Katie E. Hyma, Ph.D., counsels clients across a wide range of technologies, primarily in the life sciences, with an emphasis on biotechnology, molecular biology, and therapeutics. Her clients include emerging biotechnology startups, established companies with well-developed intellectual property portfolios, venture capital firms, and world-class academic medical and research facilities.
As a trusted advisor, Katie helps her clients to identify, protect, and optimize the value of their intellectual property with a focus on patent prosecution and counseling, as well as post-grant proceedings. Katie performs portfolio analyses, identifies third-party patent risks, and provides patentability and freedom to operate opinions. She also advises clients in all phases of due diligence, including mergers and acquisitions, fundraising, and IPOs. Her work has touched on sophisticated technologies including biologics, gene editing, cell and gene therapy, agricultural biotechnology, diagnostics and other assays, sequencing and arrays, and bioinformatics. Katie’s clients appreciate her ability to distill complex information and ideas into an understandable and actionable format.
